Add Camper Health History Signatory with airSlate SignNow

Add Camper Health History signatory

Hi, my name is Jack Aiello. I was diagnosed with stage three multiple myeloma in early 1995. At the time. I had been married for 20 years and had kids who were young, 16, 14 and ten years old. And I remember when the doctor told me that well, at my stage I was probably going to live for only 2 to 3 years. That was pretty scary. I didn't know what to say to my wife. I just remember we shared a good cry and. I remember talking to my kids and saying I had something wrong with my blood because I was going to be in the hospital for 96 hours. Meaning that instead of using my own stem cells as was done in an autologous transplant. I used donor stem cells. It worked. And I haven't been on any treatment now since the early 2000s. Something I did, right? I found that we had a myeloma support group in the Bay Area San Francisco Bay area where I live and they helped educate me about myeloma and questions I should be asking. So that made a huge difference for me. And today, whenever I talk with myeloma patients we always I always suggest that they get a second opinion from those expert doctors. And there are so many more available these days from around the world. So to set the stage I'm fortunate enough to be pretty knowledgeable about. Myeloma these days. And I am I've been asked to have a conversation about the recent ASH conference. Ash stands for American Society of Hematology, where the top doctors and researchers from around the world meet to discuss the latest in blood cancers, specifically myeloma. To those doctors are joining our conversation today. I'd like to introduce our two myeloma specialists. Dr. Josh Richter is director of multiple myeloma at the Blavatnik Family Chelsea Medical Center at Mt. Sinai. And Dr. Mohammed Baljevic is director of Plasma Cell Disorders Research at Vanderbilt University Medical Center. Both are committed to seeing myeloma patients in their clinics and also furthering research to get us those next improvements and treatments. Doctors, welcome. We will be highlighting the summary of top takeaways in myeloma from the conference. Because both of you were there. For first line therapy patients all the way through later relapse. The big buzz at Ash for myeloma patients was the word bi-specifics. But before we go there, there was some update that could actually change treatment for some myeloma patients today. And it has to do with steroids. There was also an important piece of data presented in frail, newly diagnosed patients where we demonstrated that it's possible to cut back on completely. So this is really important for patients and we've all received these questions, right? Glucocorticoids are not easy to tolerate with multitude of side effects. So in these frail patient populations where patients have multiple comorbidities, some may have diabetes, brittle diabetes that's -dependent...